SEC Comment Letter for Vaxart, Inc. (VXRT) (CIK 0000072444) (VXRT) — Feb 7, 2011

Vaxart, Inc. (VXRT) (CIK 0000072444)
Date: Feb. 7, 2011 · CIK: 0000072444 · Accession: 0000000000-11-007779

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-04829

Date

February 4, 2011

Author

Joel Parker

Form

UPLOAD

Company

Vaxart, Inc. (VXRT) (CIK 0000072444)

Letter

February 4, 2011 Raafit E. F. Fahim, Ph.D. Chief Executive Officer Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville, MD 20852 Re: Nabi Biopharmaceuticals Form 10-K for the Fiscal Year Ended December 26, 2009 Form 10-Q for the Quarterly Period Ended September 25, 2010 File No. 000-04829

Dear Dr. Fahim:

We have completed our review of your fili ngs and do not have any further comments at this time. Sincerely,

Joel Parker A c c o u n t i n g B r a n c h C h i e f

Show Raw Text

February 4, 2011
 Raafit E. F. Fahim, Ph.D. Chief Executive Officer Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville, MD 20852
Re: Nabi Biopharmaceuticals
Form 10-K for the Fiscal Year Ended December 26, 2009 Form 10-Q for the Quarterly Period Ended September 25, 2010
  File No. 000-04829

Dear Dr. Fahim:

 We have completed our review of your fili ngs and do not have any further comments at
this time.
Sincerely,

Joel Parker
        A c c o u n t i n g  B r a n c h  C h i e f

SecProbe.io